HK40081246A - Applications of mussel adhesive protein product in treatment and prevention of diseases related to melanin - Google Patents

Description

Application of mussel mucin product in treating and preventing melanin-related diseases

Technical Field

The present invention relates generally to the field of pharmaceutical, cosmetic, medical, disinfectant, health care, food and household product technology, and more particularly to mussel mucin products and their use in the treatment and prevention of melanin-related diseases.

Background

Melanin is a dark brown pigment present in animal skin or hair, produced by and stored in a particular cell, melanocytes. Melanin is widely found in the skin, mucous membrane, retina, pia mater, gall bladder, ovary, etc. of human. It is the presence of melanin that the skin has a color. Melanin is a biological pigment formed from tyrosine or 3, 4-dihydroxyphenylalanine through a series of chemical reactions and is usually present in a polymeric form.

Melanin is essentially a protein. They are present among cells in the basal layer of the skin (also called "pigment blast cells"), and are a substance called "melanogenic substance". The melanoblast secretes Maillarin pigment, when ultraviolet rays (UVA and UVB) irradiate the skin, the UVB acts on the basal layer of the skin, the skin is in a self-protection state, and the Maillarin pigment is stimulated by the ultraviolet rays to activate the activity of tyrosinase, so that the skin cells are protected. Dopa is the precursor of melanin, which is oxidized by tyrosine to release melanin. Melanin moves layer by layer through cell metabolism and reaches the skin epidermis to form freckles, sunburn, dark spots and the like.

The production of melanin is often associated with endocrine disorders and sunlight irradiation, the number of melanocytes depends on genetics and endocrine hormones and nutritional status, and diseases caused by melanin, such as pigmentation diseases, e.g., freckles, chloasma, melanosis, etc., are the subject of extensive research in the beauty industry.

The inhibition of pigments in their production is different from the treatment of pigments which have already been produced. Inhibiting pigmentation consists in halting the process from tyrosine to dopa to dihydroxyindole until melanin is produced. The process can inhibit inflammation, prevent the generation of inflammatory factors, and thus realize pigment inhibition; or by blocking the production of the pigment by means of a substance which is reactive with the substance in the process of pigment formation; or prevent pigmentation by oxidation resistance. The pigment therapy is to decompose melanin already formed by a reducing substance, so that pigment is finally disappeared.

Mussel Mucin (MAP), also known as Mussel foot protein (Mefp), is a specific protein secreted by marine Mussel common Mussel (Mytilus edulis Linnaeus), mytilus coruscus (Mytilus coruscus), perna viridis (Perna viridis) and the like. Mussels are usually attached in groups to reefs alongside the shore or to the bottom of a ship, with the ability to withstand the impact of waves offshore. In fact mussels can be attached extremely firmly to substrates of virtually any material, such as metal, wood, glass, etc. The main reason why mussels have the above properties is that they produce and store this particular mucin in their byssus glands, which they release onto solid surfaces such as rocks by means of byssus, forming a water-resistant bond, thus immobilizing themselves.

Currently, 11 mucin subclasses are identified from mussels, including mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL-P, pre-COL-D, pre-COL-NG, byssus matrix proteins PTMP and DTMP (obsidian et al, ocean science development 2014, 32 (4): 560-568). Mussel mucin has 2 structural features: (1) Contains lysine, so that the protein has high-load positive charge; (2) 3, 4-dihydroxyphenylalanine (DOPA ). Cells and tissues of the human body have negative charges. The mussel mucin is tightly combined with cells and tissues through the electrostatic interaction between the self positive charges and the negative charges of the cells and the tissues of the human body, and plays the roles of protection and treatment. In addition, dopa is oxidized to generate ortho-diquinone, which can be cross-linked with unoxidized dopa to form a membrane or a net scaffold, so that proteins can be more tightly and stably attached to the surface of a human body, and a protective effect is achieved. Mussel mucin is a macromolecular protein, is completely degraded in a human body for about 3-10 days, and has excellent capacity of being attached to cell tissues, so that the mussel mucin can be firmly fixed in a local part and continuously plays a role.

Although mussel mucin has the characteristics, the application field of the product is very limited at present. Commercially available mussel mucin products are Cell-Tak from BD Biosciences, USA, MAP Trix from Kollodis, kollidis, korlodis, and Hydrogel from Biopolymer, sweden. These products are either used directly in solution with mussel mucin or stored as a freeze-dried powder formulation which is dissolved prior to use, their main application being limited to microscopic cell adhesion and tissue adhesives. Mussel mucin has also been reported to be used for fetal membrane repair, as a seawater corrosion resistant coating, a cardiac drug-loaded stent, and the like.

Disclosure of Invention

The inventor finds that the dopa group in the mussel mucin molecule is an important substance participating in melanin synthesis as polyphenol protein, and in diseases caused by melanin such as chloasma, freckles, melanosis and the like, the dopa group in the mussel mucin molecule can enhance the activity of tyrosinase, further influence the secretion of melanin and achieve the aim of treating and preventing melanin-related diseases.

The inventor further finds that the molecular weight of the mussel mucin is up to 100kD, the absorption rate is low when the mussel mucin is directly used by skin, and the action effect is influenced. The skin surface is minimally invasive or enzymatic hydrolyzed mussel mucin is added to improve the efficiency of percutaneous action, effectively treat chloasma, freckle, melanosis and other pigmentation dermatosis, effectively inhibit skin cancer represented by melanoma, and prevent pigmentation possibly generated by skin diseases such as solarization or acne.

It is an object of the present invention to provide a mussel mucin product.

As used herein, mussel mucin refers to 11 currently known mussel mucins purified from marine mussels such as common mussels (Mytilus edulis Linnaeus), thick-shelled mussels (Mytilus coruscs) or Perna viridis (Perna viridis) among bivalve mollusks of the family mytiludae (Mytilidae): one or a mixture of more than one of mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL-P, pre-COL-D, pre-COL-NG, byssus silk matrix protein PTMP and DTMP. The pH of the mussel mucin in the aqueous solution used herein may be pH1.0-7.0, and in particular may be in the range of pH 3.0-6.5 for better therapeutic effect.

The mussel mucin used herein can be obtained by a production method such as a method for separating and purifying mussel mucin using mixed adsorption chromatography of chinese patent No. ZL200710179491.0, a method for purifying mussel mucin using carboxymethyl ion exchange chromatography of chinese patent No. ZL200710179492.5, a method for separating and purifying mussel mucin using salting out and dialysis of chinese patent No. ZL200910087567.6, and the like.

As used herein, mussel mucin may be in the form of a solution or lyophilized powder, and particularly, the concentration of mussel mucin in the product may be 0.1-15.0mg/ml, and when the concentration is too low, the efficacy of mussel mucin is poor, and when the concentration is too high, the effects of cytotoxicity, skin irritation, etc. may be caused, thus being unfavorable for the treatment of skin melanin.

The mussel mucin used herein may also be combined with an adjuvant to prepare a liquid preparation. An exemplary mussel mucin liquid agent is prepared by dissolving or diluting mother liquid or lyophilized powder of mussel mucin solution to a certain concentration or pH, and the solution for dissolving or diluting may be water, physiological saline, phosphate solution, acetate solution, borate solution, etc. The pH of the mussel mucin in the final product may be in the range of pH1.0-7.0, and may be particularly therapeutically effective in the range of pH 3.0-6.5.

Mussel mucin as used herein may also be combined with adjuvants to make gels. An exemplary mussel mucin gel is prepared by mixing a mussel mucin solution or lyophilized powder with a gel matrix material which may be one or any combination selected from cellulose derivatives, carbomers and alginates, tragacanth, gelatin, pectin, carrageenan, gellan, starch, xanthan, cationic guar, agar, non-cellulosic polysaccharides, vinyl polymers, acrylics, polyvinyl alcohol or carbopol.

Mussel mucin for use herein may also be combined with excipients to make a gel. An exemplary mussel mucin gel is prepared by mixing a mussel mucin solution or lyophilized powder with a condensation matrix which may include one of cellulose derivatives, glycerol, non-cellulosic polysaccharides, propylene glycol or any combination thereof.

The mussel mucin used herein may also be combined with excipients to make a paste. An exemplary mussel mucin paste is prepared by mixing mussel mucin with a paste base material, which may include glycerin, petrolatum, paraffin, and the like.

Mussel mucin as used herein may also be combined with a matrix material to form a dressing and application for the skin surface. An exemplary liquid in the mussel mucin dressing may be a mussel mucin solution, or a combination thereof with one or more of cellulose derivatives, carbomers and alginates, tragacanth, gelatin, pectin, carrageenan, gellan, starch, xanthan, cationic guar, agar, non-cellulosic polysaccharides, vinyl polymers, acrylics, polyvinyl or carboxyvinyl alcohols, gelatin, fish gelatin, pectin, alginates, glycerin, petrolatum, paraffin, polyethylene glycol, vitamins, glutathione. The mussel mucin solution or combination is soaked in a matrix material such as gauze, nonwoven fabric, silk paper, and the application may be, for example, a wound patch, a mask, an eye mask, a hand mask, a foot mask, etc.

The various preparations containing mussel mucin can be further added with components which are known in the art and can increase the moisture retention and oxidation resistance, such as glycerol, polyethylene glycol, vitamins, glutathione, and the like, so as to further improve the moisture retention and oxidation resistance.

The preparations containing mussel mucin can be further added with extracts of Aloe, grape seed, folium Camelliae sinensis, ginseng radix, snail, etc., amino acids, collagen protein, hyaluronic acid, etc., to increase skin and skin accessory organs nourishing ability and increase smoothness.

All of the above formulations can be prepared by methods well known in the art, and the detailed procedures can be referred to, for example, in formulation science.

Mussel mucin used herein can be used as a main raw material for the preparation of a pharmaceutical product using a pharmaceutically acceptable carrier. The medicine can be liquid, gel, paste, patch, and foam. The medicament can be used for in vitro application, in particular for external application to the skin.

Mussel mucin as used herein can be used as a major raw material for the manufacture of medical devices. The term medical device as used herein refers to materials used directly or indirectly in the human body and other similar or related items. The medical device may be a liquid, gel, paste, patch, foam. The medical device may be for in vitro use, in particular for external application to the skin.

The mussel mucin used herein can be used as a main raw material for the preparation of cosmetics using auxiliary materials acceptable in the field of cosmetics. The cosmetic can be liquid, gel, paste, patch, and foam. The cosmetic can be used in vitro, especially for external application to skin.

Mussel mucin used in the present invention can be used as a main raw material to prepare a sterilized product using an auxiliary material acceptable in the field of sterilized products. The term disinfectant product as used herein refers to disinfectants, disinfecting devices, sanitary products and disposable medical products that chemically, physically, biologically kill or eliminate pathogenic microorganisms in the environment. The disinfectant product may be a liquid, gel, paste, patch, foam. The disinfectant product is useful for in vitro use, in particular for external application to the skin.

The mussel mucin used in the method can be used as a main raw material to prepare health products or foods by adopting auxiliary materials acceptable in the field of health products or foods. The health product or food can be liquid, gel, paste, patch, and foam. The health product or food can be used for in vitro application or eating, especially for skin external application.

The mussel mucin used in the method can be used as a main raw material to prepare daily chemical products by adopting auxiliary materials acceptable in the field of daily chemical products. The term daily chemical product as used herein refers to technical chemicals commonly used on a daily basis, including shampoos, body washes, and the like. The daily chemical product can be liquid, gel, paste, plaster, and foam. The daily chemical product can be used in vitro, especially used for external application on skin.

It is another object of the present invention to provide the use of a mussel mucin product for the treatment and prevention of melanosis. In particular, it is useful for treating pigmentation-forming diseases such as chloasma, freckle and melanosis, inhibiting skin cancer such as melanoma, and preventing pigmentation which may be caused by skin diseases such as sunburn and acne.

The term treatment as used herein refers to the process of intervening or altering a particular health state, the activity performed to relieve the affliction. As used herein, the term inhibition refers to the process of weakening the original lesion after stimulation of the tissue or body.

The term prevention as used herein refers to taking a precautionary measure against a possible deviation from a subjective expected trajectory or objective general law during the course of disease treatment to avoid possible damage.

Chloasma refers to yellowish brown pigmentation of the face. It is distributed on the cheek part in a plurality of symmetrical butterflies.

Freckles are yellowish brown punctate pigmentation spots that occur on facial skin and are inherited dominantly in autosomes. It is good for the face, especially the nose and cheeks, and can involve the exposed parts of the neck, shoulders and back of the hand, while there is no rash in the unexposed parts. The damage is light brown or dark brown needle size to large macula of mung bean, round, oval or irregular. Scattered or clustered distribution, isolated and not fused.

Melanosis is a chronic inflammation of the skin resulting from prolonged exposure of workers to pitch, coal tar, petroleum-based products, or prolonged inhalation of volatiles from such substances, with resultant skin pigmentation.

Melanoma is a tumor produced by melanocytes of the skin and other organs. Cutaneous melanoma is manifested by a marked change in pigmented skin lesions over months or years.

Pigmentation caused by skin diseases is caused by inflammatory skin diseases or by various drugs. Such as solar dermatitis or acne treatment, resulting in pigmentation. Lichen planus and lichen planus-like drug eruptions cause pigmentation. Fixed drug eruptions can leave a characteristic ring-shaped pigmentation spot. The drugs that cause pigmentation include amiodarone, tetracycline, medemycin, bleomycin, cyclophosphamide, antimalarial chloroquine and quinuclidine, chlorpromazine and other phenothiazines that cause a change in the grayish blue pigmentation of the skin at the exposed area.

According to one aspect of the invention, mussel mucin can be used independently for the treatment and prevention of melanin pigmentation. When the mussel mucin is independently used for treating and preventing melanin pigmentation, the mussel mucin can be directly used or can be used after a tiny wound surface is formed. The method for forming the tiny wound surface comprises the following steps: microneedles (which may be made of silicon, silicon dioxide, cellulose, etc.), needles (which may be made of stainless steel, titanium, polytetrafluoroethylene, etc.), lasers (e.g., lattice lasers).

According to another aspect of the present invention, the mussel mucin may be combined with an enzyme for use after enzymatic degradation. Wherein the mussel mucin inhibits the oxidation process of melanin formation, and binds with dopa (3, 4-dihydroxyphenylalanine) during melanin formation to stop the further formation process of pigment. In addition, because mussel mucin has a large molecular weight, transdermal administration is difficult, and the degree that can be utilized is low, the efficiency of transdermal administration is improved by adopting enzymatic hydrolysis mussel mucin, and the treatment effect is enhanced.

The enzymes used herein may be: (1) Trypsin of various origins, such as trypsin extracted from cod pancreas, bovine pancreas, porcine pancreas, krill; (2) collagenases of various origins; (3) caspases from various sources; (4) chymotrypsin from various sources; (5) carboxypeptidases of various origins; (6) keratinases of various origins; (7) enterokinase from various sources; (8) chymosin derived from various sources. The enzyme that can be used in combination with mussel mucin for melanin treatment is not limited to the above-mentioned enzyme.

According to the present invention, mussel mucin can be used in combination with an enzyme for the treatment of melanin, and the use form can include: (1) Firstly spraying enzyme to degrade the cuticle of the skin surface, then spraying the enzyme again, and immediately spraying mussel mucin for a period of time; (2) Spraying mussel mucin, then spraying enzyme, and acting together for a period of time; (3) Mixing mussel mucin and enzyme for a period of time, and spraying; (4) Spraying enzyme and then spraying mussel mucin, and reacting for a period of time.

According to the present invention, the form of the mussel mucin and enzyme-formed product may include: (1) mussel mucin with enzymes in different packages: used separately or mixed by the user before use; (2) mussel mucinous peptide mixture: mussel mucin is prepared into a mixture of hydrolyzed peptides by adopting the various enzymes, and the product is formed after the activity of the enzymes is stopped by adopting heating and other means and is directly used; (3) mussel mucin single hydrolysis peptide: mussel mucin is prepared into a mixture of hydrolyzed peptides by adopting the various enzymes, and the enzymes are removed by adopting a separation method such as chromatography, so that the peptides without dopa groups and the peptides with unexpected molecular weight are removed, and a single peptide product only containing dopa groups is obtained and is directly used.

According to the present invention, when used for the treatment of melanin, the molar ratio of mussel mucin to enzyme is in the range of 0.1: 1 to 100: 1, preferably in the range of 1: 1 to 50: 1.

Detailed Description

Embodiments of the invention include:

1. use of mussel mucin for the treatment and prevention of melanosis.

2. The mussel mucin use according to embodiment 1, wherein the mussel mucin may be from the subclass: one or a mixture of more of mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL-P, pre-COL-D, pre-COL-NG, byssus matrix protein PTMP and DTMP.

3. The mussel mucin use according to embodiment 1, wherein the mussel mucin concentration may be 0.1-15.0mg/ml.

4. The mussel mucin use according to embodiment 1, wherein the mussel mucin can be used as a liquid, gel, paste, patch or foam.

5. The mussel mucin use according to embodiment 1, wherein the mussel mucin in the final product may be in the range of pH1.0-7.0, in particular may be in the range of pH 3.0-6.5.

6. The mussel mucin use according to any one of embodiments 1 to 5, wherein the melanin pigmentation may be pigmentation such as chloasma, freckles, melanosis, skin cancer typified by melanoma, pigmentation caused by skin diseases such as sunburn or acne.

7. The mussel mucin use according to embodiment 1, wherein the mussel mucin can be used alone or in combination with an enzyme.

8. The mussel mucin use according to embodiment 7, wherein the mussel mucin can be used directly or after the formation of a micro wound.

9. The mussel mucin use according to embodiment 8, wherein the method of forming a mini-wound bed may comprise: microneedles (which may be made of silicon, silicon dioxide, cellulose, etc.), needles (which may be made of stainless steel, titanium, teflon, etc.), lasers (e.g., lattice lasers).

10. The mussel mucin use according to embodiment 7, wherein the enzyme may be: (1) Trypsin of various origins, such as trypsin extracted from cod pancreas, bovine pancreas, porcine pancreas, krill; (2) collagenases of various origins; (3) caspases from various sources; (4) chymotrypsin from various sources; (5) carboxypeptidases of various origins; (6) keratinases of various origins; (7) enterokinase from various sources; (8) chymosin derived from various sources.

11. The mussel mucin use according to embodiment 7, wherein the mussel mucin in combination with the enzyme may comprise: (1) Firstly spraying enzyme to degrade the cuticle of the skin surface, then spraying the enzyme again, and immediately spraying mussel mucin to jointly act for a period of time; (2) Spraying mussel mucin, then spraying enzyme, and acting together for a period of time; (3) Mixing mussel mucin and enzyme for a period of time, and spraying; (4) Spraying enzyme and then spraying mussel mucin, and reacting for a period of time.

12. The mussel mucin use according to embodiment 7, wherein the mussel mucin and enzyme may be in different packages.

13. The mussel mucin use according to embodiment 7, wherein the mussel mucin is used in combination with an enzyme in the form of a mixture of mussel mucinolytic peptides.

14. The mussel mucin use according to embodiment 7, wherein the mussel mucin is used in combination with an enzyme in the form of a mussel mucin single hydrolysis peptide.

15. The mussel mucin use according to embodiment 7, wherein the molar ratio of mussel mucin to enzyme may be in the range of 0.1: 1 to 100: 1, preferably may be in the range of 1: 1 to 50: 1.

16. Use of mussel mucin as an active ingredient in a composition for the treatment and prevention of melanosis, wherein the composition is used as a liquid, gel, paste, patch or foam.

17. The mussel mucin use according to embodiment 16, wherein the composition is a composition for external application to the skin.

18. Use of mussel mucin as an active ingredient in a medicament for the treatment of melanin.

19. Use of mussel mucin as an active ingredient in a medical device for the treatment of melanin.

20. Use of mussel mucin as an active ingredient in a cosmetic for the treatment of melanin.

21. Use of mussel mucin as an active ingredient in a disinfecting product for the treatment of melanin.

22. Use of mussel mucin as an active ingredient in a health product or food for the treatment of melanin.

23. Use of mussel mucin as an active ingredient in a daily chemical product for the treatment of melanin.

24. The mussel mucin use according to any of embodiments 16-23, wherein the mussel mucin is used in combination with an enzyme.

25. A medicine for treating melanin pigmentation comprises mussel mucin and pharmaceutically acceptable carrier, wherein the concentration of mussel mucin is 0.1-15.0mg/ml.

26. A medical device for treating melanin pigmentation, comprising mussel mucin and a vehicle acceptable in the medical device field, wherein the concentration of the mussel mucin is 0.1-15.0mg/ml.

27. A cosmetic for treating melanosis comprises mussel mucin and a cosmetically acceptable carrier, wherein the mussel mucin is present in a concentration of 0.1-15.0mg/ml.

28. A disinfectant product for treating melanosis comprises mussel mucin and a carrier acceptable in the field of disinfectant products, wherein the concentration of mussel mucin is 0.1-15.0mg/ml.

29. A health product/food for treating melanin pigmentation comprises mussel mucin and a carrier acceptable in health product/food field, wherein the concentration of mussel mucin is 0.1-15.0mg/ml.

30. A daily chemical product for treating melanin pigmentation comprises mussel mucin and a carrier acceptable in daily chemical product field, wherein the concentration of mussel mucin is 0.1-15.0mg/ml.

31. The pharmaceutical product according to any one of embodiments 25-30, further comprising an enzyme.

The present invention will be further described with reference to the following specific examples. It is to be noted that the pharmaceutical, medical device, cosmetic, disinfectant, health care, or food, daily chemical products formed from the mussel mucin or the preparations of the mussel mucin of the invention can be applied to the indications and exhibit the functions described above after administration to a subject, and all the dosage forms within the scope of the invention have been tested, and hereinafter, only a few of them are described in the examples, but they should not be construed as limiting the invention.

Unless otherwise specified, the reagents used in the present invention are commercially available.

Example 1: the application of mussel mucin gel cosmetic in treating chloasma is provided.

Mixing the mussel mucin solution with polyvinyl alcohol, hydroxypropyl cellulose and glycerol according to the mass ratio of 2: 1: 2 to obtain the mussel mucin gel cosmetic with the mussel mucin concentration of 3 mg/g.

10 chloasma cases are collected, the affected part of the selected patient is required to be a cheek part, the color of the plaque is dark brown, and the patient is subjected to grouping test after being diagnosed by a dermatologist. The mussel mucin gel cosmetic is applied to the affected part 1 time a day, and can be uniformly applied to the surface of the affected part every time. The pigment value of the affected part is measured by a pigment measuring instrument every 10 days, and after 10 patients apply the mussel mucin gel cosmetic for 50 days, the pigment value of the affected part is reduced by 9 percent (see table 1), which proves that the pigment deposition at the chloasma can be reduced by using the mussel mucin product for a long time.

Table 1:

mean value of pigment at affected part on day 0	308±10.7
		Average value of pigment after 10 days of use	303.4±9.9
Average value of pigment after 20 days of use	299.2±9.5
		Average value of pigment after 30 days of use	293.6±8.2
Average value of pigment after 40 days of use	286.6±5.8
		Average value of pigment after 50 days of use	280.6±6.8

Example 2: the application of mussel mucin dew daily chemical product in treating chloasma is provided.

Mixing the mussel mucin solution with propylene glycol and glycerol according to the mass ratio of 2: 1 to obtain the mussel mucin gel daily chemical product with the mussel mucin concentration of 1.5 mg/g.

10 chloasma cases are collected, the affected part of the selected patient is required to be the cheek part, the spot color is dark brown, and the selected patient is subjected to the grouping test after being diagnosed by a dermatologist. The mussel mucin gel daily chemical product is applied to the affected part for 2 times a day, and can be uniformly applied to the surface of the affected part every time. The pigment value of the affected part is measured by a pigment measuring instrument every 10 days, and after 10 patients are coated with the mussel mucin condensation daily chemical product for 50 days, the pigment value of the affected part is reduced by 7.3 percent (see table 2), which proves that the pigment deposition at the chloasma part can be reduced by using the mussel mucin product for a long time.

Table 2:

mean value of pigment at affected part on day 0	316.0±13.6
		Average value of pigment after 10 days of use	313.8±9.3
Average value of pigment after 20 days of use	309.4±7.8
		Average value of pigment after 30 days of use	302.3±7.2
Average value of pigment after 40 days of use	298.6±6.9
		Average value of pigment after 50 days of use	293.9±8.2

Example 3: the application of mussel mucin liquid medical appliance in treating chloasma.

A mussel mucin solution (1 ml) with a concentration of 20.0mg/ml is taken, and 9ml of a 0.1% citric acid solution is added to prepare an aqueous solution with a mussel mucin concentration of 2.0 mg/ml. 1.0mg of cod enzyme was added to 1.0ml of deionized water to prepare a solution having a concentration of 1.0 mg/ml.

30 patients with chloasma confirmed by a dermatologist were collected for the test. The affected part of the patient has a yellowish brown color.

Patients selected are randomly divided into three groups, wherein the first group is smeared on affected parts by adopting a commercially available freckle removing liquid and is marked as a group A. The second group adopts the mussel mucin liquid medical apparatus to spray the affected part and is marked as group B; the third group adopts the composition of mussel mucin liquid medical apparatus and enzyme to spray on the affected part, when in use, the mussel mucin is sprayed firstly, and then the enzyme preparation is sprayed, which is marked as group C. The three groups of patients all take the medicine 3 times daily, and the dosage of the medicine can be uniformly applied to affected parts. Before application, the melanin value of affected part and the melanin value of the area without color spot around the affected part are measured. The melanin value of the affected part was measured every 10 to 30 days, and the change rate of the melanin of the affected part was calculated (see table 3).

The melanin change rate was calculated using the following formula:

(pre-application melanin value-post-application melanin value)/(pre-application melanin value-normal part melanin value) × 100%

Table 3:

the results show that: compared with the commercially available freckle removing products, the change rate of the pigment value of the affected part is more than doubled after the mussel mucin liquid medical appliance is used for 90 days, and the freckle removing effect is better than that of the commercially available products. After the mussel mucin liquid medical appliance and the enzyme are used in combination for 90 days, the change rate of the pigment value of the affected part reaches 28.2 percent, and the effect of obviously improving chloasma of the affected part is achieved. In addition, compared with the single use of the mussel mucin product, the combination use of the mussel mucin product and the enzyme can double the change rate of the pigment value of the affected part, which is more beneficial to the treatment of chloasma.

Example 4: the mussel mucinization hydrogel cosmetic can be used for treating chloasma.

Taking 10g of sodium carboxymethylcellulose, adding 20ml of deionized water, carrying out warm bath at 90 ℃ for 30min until the sodium carboxymethylcellulose is completely dissolved to obtain a gel matrix, taking 2.5ml of mussel mucin solution with the concentration of 10.0mg/ml, adding the mussel mucin solution into the gel matrix while stirring, and uniformly mixing to form the mussel mucinized hydrogel cosmetic, wherein the mussel mucin concentration is 1.1mg/ml. 1.0mg of cod enzymes is taken and added with 1.0ml of deionized water to prepare a solution with the concentration of 1.0 mg/ml.

20 chloasma patients confirmed by dermatologists were collected for testing. The affected part of the patient has yellowish brown.

The mussel mucin hydrogel cosmetic is sprayed on the affected part of a selected patient, and when the mussel mucin hydrogel cosmetic is used, the mussel mucin hydrogel cosmetic is sprayed first, and then the enzyme preparation is sprayed, 3 times a day. The melanin value of the affected part and the melanin value of the area without color spots around the affected part are measured before use. The melanin value of the affected part was measured every 10 to 30 days, and the rate of change of melanin in the affected part was calculated (see table 4 for the results).

The melanin change rate was calculated using the following formula:

(melanin value before use-melanin value after use)/(melanin value before use-melanin value at normal position) x 100%

Table 4:

application time (sky)	Melanin change ratio (%)
		10	9.6±1.6
30	18.2±1.9
		60	29.6±2.7
90	38.4±1.8

The results show that: after using the mussel mucin hydrogel cosmetic and enzyme for 10 days, the pigment value of the affected part begins to decrease, and the change rate of the melanin of the affected part increases along with the prolonging of the using time, until the pigment of the affected part changes by more than 1/3 after 90 days of using. The mussel mucin product of the invention can reduce the pigmentation at the chloasma and can be used for treating the chloasma.

Example 5: the application of mussel mucin liquid medicine in the treatment of freckle is provided.

1ml of mussel mucin solution with the concentration of 10.0mg/ml is taken, and 9ml of 0.1% citric acid solution is added to prepare the liquid medicine with the mussel mucin concentration of 1.0 mg/ml. 1.0mg of trypsin was added to 1.0ml of deionized water to prepare a solution with a concentration of 1.0 mg/ml.

20 cases of freckle patients confirmed by dermatologists were collected for testing. The affected part of the patient has a flaky brown spot.

The selected patient adopts the mussel mucin liquid medicine to spray on the affected part, and when in use, the mussel mucin is firstly sprayed on the liquid medicine and then the enzyme preparation is sprayed on the affected part, 3 times a day. The melanin value of the affected part and the melanin value of the area without color spots around the affected part are measured before use. The melanin value of the affected part was measured every 10 to 30 days, and the rate of change of melanin was calculated (see table 5).

The melanin change rate was calculated using the following formula:

(pre-application melanin value-post-application melanin value)/(pre-application melanin value-normal site melanin value) × 100%

Table 5:

service time (sky)	Melanin change ratio (%)
		10	6.4±1.4
30	21.6±2.8
		60	28.7±2.9
90	35.2±3.6

The results show that: after the mussel mucin liquid medicine and the enzyme are used for 10 days, the pigment value of the affected part begins to decline, the change rate of the melanin of the affected part is increased along with the prolonging of the use time, and the pigment change of the affected part reaches 35.2 percent after the mussel mucin liquid medicine and the enzyme are used for 90 days, which proves that the mussel mucin product can reduce the pigmentation of freckle patients and can be used for treating the freckles.

Example 6: the application of the mussel mucin dew daily chemical product in the treatment of freckles.

Mixing propylene glycol and glycerol at a ratio of 1: 1 to form a condensation matrix, adding 2.5ml of mussel mucin solution with a concentration of 10.0mg/ml into the condensation matrix while stirring, and uniformly mixing to form a mussel mucin condensation daily chemical product with a mussel mucin concentration of 3.0mg/ml.

30 cases of freckle patients confirmed by dermatologists were collected for testing. The affected area of the patient had a flaky brown plaque.

Enrolled patients were randomly divided into three groups, the first group using a commercially available spot removing lotion, designated as group a. The second group directly uses the mussel mucin dew daily chemical product to be smeared on the affected part and is marked as group B; and the third group adopts micro-needles to form micro wound surfaces on the affected parts, and then the mussel mucin dew daily chemical product is smeared on the affected parts and is marked as group C. The three groups are administered 3 times daily, and the dosage is enough to be applied to affected part. Before application, the melanin value of affected part and the melanin value of the area without color spot around the affected part are measured. The melanin value of the affected part was measured every 10 to 30 days after using mussel protein, and the rate of change of melanin in the affected part was calculated (see table 6).

The melanin change rate was calculated using the following formula:

(pre-application melanin value-post-application melanin value)/(pre-application melanin value-normal site melanin value) × 100%

Table 6:

the results show that: compared with the commercial products, the change rate of melanin is improved by 3 times after the mussel mucin gel daily chemical product is used for 90 days. After the mussel mucin gel daily chemical product and the enzyme are used in combination for 90 days, the change rate of the pigment value of the affected part reaches 42.6 percent, and the effect of obviously improving freckle and pigmentation of the affected part is achieved. In addition, compared with the single use of the mussel mucin product, the combination use of the mussel mucin product and the enzyme can improve the change rate of pigment value of the affected part by 2.5 times, which is more beneficial to the treatment of freckles.

Example 7: application of mussel mucin gel cosmetic in treating melanosis is provided.

Mixing the mussel mucin lyophilized powder with gelatin, fish gelatin and glycerol at a ratio of 3: 1: 0.5 to obtain the mussel mucin gel cosmetic with a mussel mucin concentration of 5.5mg/ml.

12 patients with melanosis, diagnosed by a dermatologist, were collected and given the mussel mucin gel cosmetic described above 2 times daily in an amount to completely cover the test area for 90 consecutive days.

Pigment content of affected part is measured by pigment measuring instrument, and after 20 days, average pigment value of affected part begins to decrease to about 96% of initial value. By day 90, the pigmentation value of the affected area decreased to 82.6% of the initial value (see Table 7), demonstrating that the use of the mussel mucin product of the invention can reduce melanosis pigmentation.

Table 7:

example 8: the application of the mussel mucin gel health care product in the treatment of melanosis.

Mixing mussel mucin solution with gelatin and glycerol at a ratio of 1: 1 to form mussel mucin gel health product with mussel mucin concentration of 10.0mg/ml.

12 patients with melanosis diagnosed by a dermatologist were collected and given 2 times daily the mussel mucin gel health product in an amount to completely cover the test area for 90 consecutive days.

Pigment content of affected part is measured by pigment analyzer, and after 20 days, average pigment value of affected part begins to decrease to 96% of initial value. By day 90, the pigmentation value of the affected area decreased to 80% of the initial value (see Table 8), demonstrating that the use of the mussel mucin product of the invention reduces melanosis pigmentation.

Table 8:

mean value of pigment at affected part on day 0	353.3±43.1
		Average value of pigment after 20 days of use	341.7±36.4
Average value of pigment after 40 days of use	316.6±25.6
		Average value of pigment after 60 days of use	300.3±24.8
Average value of pigment after 80 days of use	290.9±19.6
		Average pigment value after 90 days of use	282.2±24.9

Example 9: the application of the mussel mucin liquid health product in the treatment of melanosis is provided.

10ml of mussel mucin solution with the concentration of 10.0mg/ml is taken and added with 10ml of 0.001% acetic acid solution to prepare aqueous solution with the mussel mucin concentration of 5.0mg/ml.

12 patients with melanosis confirmed by a dermatologist were collected for the test. The patient forms a micro wound surface on the test surface by using a laser minimally invasive technology, and then uses the mussel mucin liquid health care product for 2 times a day, the dosage is enough to completely cover the test area, and the mussel mucin liquid health care product is continuously used for 90 days.

Before application, the melanin value of affected part and the melanin value of the area without color spot around the affected part are measured. The melanin value of the affected part was measured every 10 to 30 days, and the rate of change of melanin was calculated (see table 9).

The melanin change rate was calculated using the following formula:

(pre-application melanin value-post-application melanin value)/(pre-application melanin value-normal part melanin value) × 100%

Table 9:

the results show that: after the mussel mucin liquid health care product is used, the pigment value of the affected part begins to decline, the change rate of melanin of the affected part is increased along with the prolonging of the use time, and the pigment change of the affected part reaches 42.2 percent after the mussel mucin liquid health care product is used for 90 days, which proves that the mussel mucin product can reduce the pigmentation of patients with melanosis and can be used for treating the melanosis.

Example 10: the application of the mussel mucinous hydrogel medical appliance in the treatment of melanosis.

Mussel mucin, carbomer and propylene glycol are mixed according to the mass ratio of 1: 2 to form the mussel mucin hydrogel medical appliance, wherein the concentration of the mussel mucin is 2.5mg/ml.

12 patients with melanosis confirmed by a dermatologist were collected for the test. The patient forms a micro wound surface on the test surface by using a needle roller minimally invasive technology, and then uses mussel mucin hydrogel medical instrument for 2 times a day, and the dosage is enough to completely cover the test area for 90 days.

The melanin value of the affected part and the melanin value of the area without color spots around the affected part are measured before use. The melanin value of the affected part was measured every 10 to 30 days after using mussel protein, and the rate of change of melanin in the affected part was calculated (see table 10 for the results).

The melanin change rate was calculated using the following formula:

(melanin value before use-melanin value after use)/(melanin value before use-melanin value at normal position) x 100%

Table 10:

service time (sky)	Melanin change ratio (%)
		10	10.3±1.6
30	23.6±3.1
		60	31.8±2.8
90	39.2±3.5

The results show that: after the mussel mucin hydrogel medical appliance is used for 10 days, the pigment value of the affected part begins to decline, the change rate of melanin of the affected part is increased along with the prolonging of the use time, and the pigment change of the affected part reaches 39.2 percent after the mussel mucin hydrogel medical appliance is used for 90 days, which proves that the mussel mucin product can reduce the pigmentation of patients with melanosis and can be used for treating the melanosis.

Example 11: application of mussel mucin liquid cosmetic in inhibiting melanin precipitation after burn is provided.

Adding 0.01% citric acid into mussel mucin solution to adjust pH to 4.0 to obtain mussel mucin liquid cosmetic with mussel mucin concentration of 10.0mg/ml.

5 patients in the healing period after burn are collected, the burn area of the patients is more than 2 percent of the surface area of the human body, and the patients voluntarily sign informed consent to participate in the test. The mussel-sticky egg is applied to the liquid cosmetic for 3 times every day, and the dosage of the mussel-sticky egg is controlled so that the mussel-sticky egg can uniformly cover the affected part. The test is carried out by selecting adjacent area of the same body for control, i.e. selecting two areas of the same body, one part using the mussel mucin liquid cosmetic (test group), and the other part treating according to normal middle program (control group). The pigments of the test, control and healthy skin were measured using day 0, day 7 and day 14, respectively (see table 11). After 14 days of treatment, the skin after burn rehabilitation using the mussel mucin liquid cosmetic has no obvious pigmentation, and the unused skin has obvious pigmentation.

Table 11:

	healthy skin pigment	Skin pigment of test group	Skin pigment of control group
				Day 0	138.7±5.8	139.6±6.1	139.6±6.1
Day 7	138.7±5.8	142.6±4.3	157.4±5.5
				Day 14	138.7±5.8	145.2±4.9	170.2±6.0

The application is a divisional application of an invention patent application with the application date of 2015, 7-month and 20-month, and the application number of 201580081661.4 (international application number of PCT/CN 2015/084494), namely application of a mussel mucin product in treating and preventing melanin-related diseases.

Claims (10)

1. Use of mussel mucin for the treatment and prevention of melanosis.

2. The mussel mucin use according to claim 1, wherein the mussel mucin is from the subclass: one or a mixture of more of mefp1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, collagen pre-COL-P, pre-COL-D, pre-COL-NG, byssus matrix protein PTMP and DTMP.

3. The mussel mucin use according to claim 1, wherein the mussel mucin concentration is 0.1-15.0mg/ml.

4. The mussel mucin use according to claim 1, wherein the mussel mucin is used in a liquid, gel, paste, patch or foam.

5. The mussel mucin use according to claim 1, wherein the mussel mucin in the final product is in the range of pH1.0-7.0, especially may be in the range of pH 3.0-6.5.

6. The use of mussel mucin according to any of claims 1 to 5, wherein the melanin pigmentation is pigmentation such as chloasma, freckles, melanosis, skin cancer typified by melanoma, pigmentation caused by skin diseases such as sun burn or acne.

7. The mussel mucin use according to claim 1, wherein the mussel mucin is used alone or in combination with an enzyme.

8. The mussel mucin use according to claim 7, wherein the mussel mucin is used directly or after a micro wound is formed.

9. The mussel mucin use of claim 8, wherein the means for creating microscopic wound surfaces comprises microneedles, needles, lasers.

10. The mussel mucin use according to claim 7, wherein the enzyme is: trypsin from various sources; collagenases of various origins; various sources of casein protease; chymotrypsin from various sources; carboxypeptidases of various origins; keratinases of various origins; enterokinase from various sources; and chymosin from various sources.